biocrea GmbH
biocrea discovers and develops novel drugs for the treatment of debilitating CNS diseases such as schizophrenia or Huntington’s disease.
The company’s team has an exceptional track record in the development of CNS drug candidates and has partnered extensively with major pharmaceutical companies such as Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. biocrea is based in Radebeul, Germany.
